Celiac Disease Clinical Trials

Find Celiac Disease Clinical Trials Near You

Celiac Autoimmunity and Risk Evaluation Strategies for Type 1 Diabetes in Pediatric Patients

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Celiac disease (CD) and type 1 diabetes mellitus (T1D) are chronic autoimmune disorders that frequently co-occur, largely due to shared genetic susceptibility, particularly HLA-DQ2 and HLA-DQ8 alleles. In Italy, approximately 300,000 individuals are affected by T1D, with a prevalence of 0.5% in the general population and 0.22% in the pediatric population. The annual incidence among children is 12.26 per 100,000, with boys affected more frequently than girls (13.13 vs. 11.35 per 100,000). Alarmingly, 25-40% of pediatric patients present with diabetic ketoacidosis (DKA) at disease onset. International prospective studies, such as the Environmental Determinants of Diabetes in the Young (TEDDY) study, have demonstrated that symptoms are poor predictors of CD autoimmunity, emphasizing the need for structured population-based screening strategies. Similarly, in T1D, the appearance of disease-specific autoantibodies-such as anti-GAD, insulin autoantibodies (IAA), IA-2A, and ZnT8A-can precede the onset of clinical disease by years. Identifying these markers enables early risk stratification, timely monitoring, and potential enrollment in immunomodulatory prevention trials, including those organized by TrialNet. In this context, an observational study is being conducted at the Pediatric Department of the University of Bari. It involves the prospective screening of children (ages 1 to 18 years) with a confirmed diagnosis of celiac disease for T1D-associated autoantibodies. The study aims to enroll 600 CD patients over one year, with an anticipated 80% participation rate among eligible families.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 18
Healthy Volunteers: f
View:

• Children aged 1-18 years with biopsy-confirmed CD.

• Informed consent from parents/legal guardians and assent from the child (as applicable).

Locations
Other Locations
Italy
University Of Bari Aldo Moro-Pediatric Gastroenterology Section
RECRUITING
Bari
Contact Information
Primary
Ruggiero Francavilla, Prof
rfrancavilla@gmail.com
00390805592063
Backup
Fernanda Cristofori, MD
fernandacristofori@gmail.com
00393384176598
Time Frame
Start Date: 2026-01-01
Estimated Completion Date: 2026-12-30
Participants
Target number of participants: 600
Treatments
Celiac paediatric patients
600 pediatric subjects will be enrolled, all with a confirmed diagnosis of celiac disease according to the 2020 ESOPGHAN criteria.
Sponsors
Leads: University of Bari

This content was sourced from clinicaltrials.gov